ERBB2 and breast carcinoma: 18F-Z HER2-Affibody, in contrast to FDG, is shown as a promising radiotracer for the characterization of HER2-positive breast cancer metastases because it characterizes HER2-positive lesions with higher precision than 18F-FDG [3].